Senseonics Holdings Inc
Change company Symbol lookup
Select an option...
SENS Senseonics Holdings Inc
PCLB Pinnacle Bancshares Inc
CPSS Consumer Portfolio Services Inc
STRT Strattec Security Corp
COHU Cohu Inc
MGRC McGrath RentCorp
GOVX Geovax Labs Inc
RCKT Rocket Pharmaceuticals Inc
PTIE Pain Therapeutics Inc
PFG Principal Financial Group Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap GrowthCompany profile

Senseonics Holdings, Inc. is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes. The Company's Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user's mobile device, such as a smartphone, Apple Watch or tablet.

Closing Price
$2.64
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
2,165,902
0

GE's stock surges toward 6th straight gain after reports of jet-leasing business sale prompts upgrade

2:45 pm ET January 7, 2019 (MarketWatch)
Print

Shares of General Electric Co. (GE) powered up 5.5% toward a sixth-straight gain in afternoon trade Monday, enough to pace its industrial-sector peers, after Bloomberg reported (http://www.marketwatch.com/story/ge-stock-rise-after-report-of-apollo-interest-in-jet-lease-business-2019-01-04) that Apollo Global Management LLC (APO) was readying a bid to buy GE's jet-leasing business, which could be valued at as much as $40 billion. CFRA analyst Jim Corridore followed by upgrading GE to buy from hold, and lifted his price target to $11, which is about 27% above current levels. "With GE preparing to spin-off healthcare and sell-off its share in Baker-Hughes, we think this news could provide a path to fix GE's highly leveraged balance sheet," Corridore wrote in a note to clients. Meanwhile, J.P. Morgan analyst Stephen Tusa, the long-time bear who caused a stir last month when he upgraded GE to neutral from underweight, said he struggles to see support for a $40 billion valuation, and believes the business is worth closer to $30 billion, and doesn't believe a sale would be the "silver bullet" to leverage issues that bulls expect. He reiterated his $6 stock price target, which is 31% below current levels. The stock has gained 29.5% over the past since it closed at a 9 1/2-year low of $6.71 on Dec. 12, while the SPDR Industrial Select Sector ETF (XLI) has declined 3.7% and the Dow Jones Industrial Average has lost 4.0% over the same time.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 07, 2019 14:45 ET (19:45 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.